CTOR (Citius Oncology) ROE % Adjusted to Book Value: -138.55% (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.66
! 2 Warning Signs
View Full Analysis

What is Citius Oncology ROE % Adjusted to Book Value?

Citius Oncology CTOR 10 ROE % Adjusted to Book Value is -138.55% as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Citius Oncology's ROE % for the quarter that ended in Mar. 2026 was -227.23%. Citius Oncology's PB Ratio for the quarter that ended in Mar. 2026 was 1.64. Citius Oncology's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -138.55%.

Citius Oncology ROE % Adjusted to Book Value Related Terms

Citius Oncology ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Citius Oncology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology ROE % Adjusted to Book Value Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
ROE % Adjusted to Book Value
0.00 0.00 -27.32 -14.40

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.02 -6.58 -13.69 -29.57 -138.55

CTOR vs INCR, BGM, CPIX: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Citius Oncology's ROE % Adjusted to Book Value falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology ROE % Adjusted to Book Value Calculation

Citius Oncology's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-54.42% / 3.78
=-14.40%

Citius Oncology's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-227.23% / 1.64
=-138.55%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -138.55% mean?
Citius Oncology (CTOR) has a ROE % Adjusted to Book Value of -138.55% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's ROE % Adjusted to Book Value too high?
Citius Oncology's current ROE % Adjusted to Book Value is -138.55%. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's ROE % Adjusted to Book Value compare to INCR and BGM?
Citius Oncology's ROE % Adjusted to Book Value of -138.55% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Citius Oncology and its competitors. Citius Oncology's current ROE % Adjusted to Book Value is -138.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current ROE % Adjusted to Book Value of -138.55%. The current ROE % Adjusted to Book Value is -138.55%. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Citius Oncology (CTOR), the current ROE % Adjusted to Book Value is -138.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price